Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 266.50
Bid: 261.50
Ask: 266.50
Change: 2.00 (0.76%)
Spread: 5.00 (1.912%)
Open: 266.50
High: 266.50
Low: 266.50
Prev. Close: 264.50
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Chi-Med to Announce 2019 Half-Year Results

3 Jul 2019 07:00

RNS Number : 3198E
Hutchison China Meditech Limited
03 July 2019
 

Chi-Med to Announce 2019 Half-Year Financial Results

 

London: Wednesday, July 3, 2019: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2019 on Tuesday, July 30, 2019 at 7:00 am British Summer Time (BST) (2:00 pm Hong Kong Time (HKT); 2:00 am Eastern Daylight Time (EDT)).

 

An analyst presentation will be held at 9:00 am BST (4:00 pm HKT) on the same day at Citigate Dewe Rogerson, 8th Floor, Holborn Gate, 26 Southampton Buildings, London WC2A 1AN, UK, which will be webcast via the company website at www.chi-med.com/investors/event-information/. The presentation will be available to download before the analyst presentation begins.

 

For North America based analysts and investors, Chi-Med will also host a conference call with Q&A at 9:00 am EDT (2:00 pm BST).

 

Details of the analyst presentation and conference call dial-in will be provided in the financial results announcement. A replay will also be available on the website shortly after each event.

 

About Chi-Med

Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 440 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med's Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.

 

Chi-Med is headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.

 

CONTACTS

Investor Enquiries

 

Mark Lee, Senior Vice President, Corporate Finance & Development

+852 2121 8200

Annie Cheng, Vice President, Corporate Finance & Development

+1 (973) 567 3786

David Dible, Citigate Dewe Rogerson

+44 7967 566 919 (Mobile) david.dible@citigatedewerogerson.com

Xuan Yang, Solebury Trout

+1 (415) 971 9412 (Mobile)xyang@troutgroup.com

Media Enquiries

UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson

+44 7973 611 888 (Mobile)anthony.carlisle@cdrconsultancy.co.uk

Americas - Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile)bmiles@troutgroup.com

Hong Kong & Asia ex-China

- Joseph Chi Lo, Brunswick

+852 9850 5033 (Mobile)jlo@brunswickgroup.com

- Zhou Yi, Brunswick

+852 9783 6894 (Mobile)yzhou@brunswickgroup.com

Mainland China - Sam Shen, Edelman

+86 136 7179 1029 (Mobile)sam.shen@edelman.com

Nominated Advisor

Richard Gray / Atholl Tweedie, Panmure Gordon (UK) Limited

+44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORCKNDBPBKKPOK
Date   Source Headline
28th Mar 20247:00 amRNSSavolitinib sNDA Accepted in China
22nd Mar 20247:00 amRNSInitiation of Registration Stage of P2/3 Trial
14th Mar 20249:00 amRNSLTIP and Share Option Scheme
5th Mar 20248:30 amRNSVesting of awards under the LTIP
28th Feb 202412:45 pmRNSPublication of Form 20-F
28th Feb 202411:30 amRNS2023 Full Year Results and Business Updates
7th Feb 20247:00 amRNSPresentation of Phase III Data on Fruquintinib
2nd Feb 20248:37 amRNSInmagene Exercises Option for Two Drug Candidates
1st Feb 20248:30 amRNSHUTCHMED to Announce 2023 Final Results
30th Jan 20247:12 amRNSHUTCHMED Receives Marketing Approval in Hong Kong
11th Jan 20247:00 amRNSSovleplenib NDA Granted Priority Review in China
29th Dec 20238:30 amRNSTotal Voting Rights
29th Dec 20238:30 amRNSBlocklisting Six Monthly Return
21st Dec 202310:00 amRNSOverseas Regulatory Announcement
13th Dec 20237:00 amRNSInclusion in National Reimbursement Drug List
13th Dec 20237:00 amRNSCompleted Enrollment of Phase II/III Trial
7th Dec 202310:04 amRNSOverseas Regulatory Announcement
1st Dec 20237:00 amRNSClinical Data to be Presented at Congresses
30th Nov 20238:30 amRNSTotal Voting Rights
9th Nov 20237:00 amRNSU.S. FDA Approval of FRUZAQLAâ„¢ (fruquintinib)
24th Oct 20239:30 amRNSVesting of awards under the LTIP
16th Oct 20239:30 amRNSClinical Data to be Presented at ESMO 2023
29th Sep 20239:30 amRNSNDA Submission for Fruquintinib in Japan
29th Sep 20239:30 amRNSTotal Voting Rights
14th Sep 20239:30 amRNSDirector’s Share Dealing
12th Sep 20239:30 amRNSPhase IIIb Savolitinib Results at WCLC 2023
12th Sep 20237:00 amRNSPatient Enrollment Completed for Bridging Study
31st Aug 20239:30 amRNSTotal Voting Rights
29th Aug 20237:00 amRNSBTD in China for Savolitinib for Gastric Cancer
21st Aug 20237:00 amRNSSovleplenib Phase 3 Study Meets Primary Endpoint
7th Aug 20239:30 amRNSExercise of Share Options by a Director
31st Jul 202312:00 pmRNSInterim Results and Business Updates
20th Jul 20237:00 amRNSBreakthrough Therapy Designation for Fruquintinib
13th Jul 20239:30 amRNSChanges to Board and Technical Committee
10th Jul 20237:00 amRNSPhase 1 Study of HMPL-415 Initiated
29th Jun 20239:30 amRNSBlocklisting Six Monthly Return
26th Jun 20239:30 amRNSHUTCHMED to Announce 2023 Half-Year Results
16th Jun 20237:00 amRNSPhase III FRESCO-2 Results in The Lancet
15th Jun 20233:39 pmRNSMAA of Fruquintinib Validated by the EMA
9th Jun 202310:30 amRNSHUTCHMED Highlights Presentations at EHA and ICML
6th Jun 202310:00 amRNSLTIP and Share Option Scheme
31st May 20239:30 amRNSTotal Voting Rights
26th May 20237:00 amRNSFruquintinib NDA Granted Priority Review by FDA
26th May 20237:00 amRNSHUTCHMED Highlights Presentations at ASCO 2023
17th May 20239:30 amRNSStandard form for notification of major holdings
12th May 20231:15 pmRNSAnnual General Meeting Poll Results
12th May 20239:30 amRNSBoard of Directors and Board Committee Membership
10th May 20239:30 amRNSAppointment of Independent NED
28th Apr 20239:30 amRNSTotal Voting Rights
21st Apr 20239:30 amRNSVesting of awards under the LTIP

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.